. 2014 Oct 28;20(40):14537–14558. doi: 10.3748/wjg.v20.i40.14537

Table 3.

Phase II/III trials of anti-epidermal growth factor receptor agents for advanced gastric cancer and gastro-esophageal junction cancer

Trial	Phase	Setting	Regimen	Patients (n)	RR	OS (mo)	TTP (mo)
FOLCETUX[187], 2007	II	1^st line	FOLFIRI + Cet	38	44.1%	16.0	8.0
NCT00477711[188], 2008	II	1^st line	CX + Cet	54	48.1%	-	5.23
DOCETUX[95], 2009	II	1^st line	C + TXT + Cet	72	41.2%	9.0	5.0
AIO[93], 2010	II	1^st line	FUFOX + Cet	52	65.0%	9.5	7.6
NCT01123811[94], 2011	II	1^st line	FOLFIRI + Cet	49	46.0%	16.5	90.0
NCT00398398[189], 2011	II	1^st line	XELOX + Cet	44	52.3%	11.8	6.5
NCT00517829[96], 2013	II	1^st line	DOCOX	75	26.5%	8.5	-
NCT00517829[96], 2013	II	1^st line	DOCOX + Cet	75	38.0%	9.4	-
EXPAND[97], 2013	III	1^st line	CX + Cet	455	29.0%	9.4	4.4
			CX	449	30.0%	10.7	5.6
REAL-III[103], 2013	II-III	1^st line	EOX + P	278	42.0%	8.8	6.0
			EOX	275	46.0%	11.3	7.4
NCT00113581[107], 2008	I	1^st line	ECX + M	21	65.0%	-	5.2
MATRIX[190], 2010	II	1^st line	ECX + M	35	58.0%	12.2	7.1
MATRIX[190], 2010	II	1^st line	ECX	35	31.0%	9.4	4.8
NCT01813253[111], 2011	II	2^nd line	Iri	82	18.4%	7.5%	85 d
NCT01813253[111], 2011	II	2^nd line	Iri + N	82	10.3%	9.7%	73 d

Cet: Cetuximab; C: Cisplatin; TXT: Docetaxel; X: Capecitabine; E: Epirubicin; O: Oxaliplatin; P: Panituimumab; E: Epirubicin; Iri: Irinotecan; M: Matuzumab; N: Nimotuzumab; FOLFIRI: 5 fluorouracil plus folinic acid plus irinotecan; FUFOX: 5 fluorouracil plus oxaliplatin; DOCOX: Docetaxel plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin; RR: Response rate; OS: Overall survival; TTP: Time to progression.